AG Moriggl
Top Mutations
We have investigated at length JAK-STAT pathway loss and hyperactivation. Our new direction is core cancer pathway integration of cytokine and growth factor signaling through RAS-RAF-MAPK, PI3K-AKT-mTOR, and JAK-STAT driver mutations in patient contexts. We seek to investigate this oncogenesis through establishment of robust tumor microenvironment assays with patient specificity and combinatorial drug targeting.
Molecular Devices
MolDev establishes with Mag. Martina Sykora a high-throughput screening platform for organoids. We explore drug synergies and novel readouts.
RIANA
Richard Moriggl is a cofounder of RIANA Therapeutics GmbH based in Vienna. It is run by Dr. Anna Orlova, developing STAT5 inhibitors.
DSP
We have an international doctoral school program to which you can apply as a PhD student. It offers a structured, rigorous program with mentoring.
CTBI
The Center for Tumor Biology and Immunology (CTBI) is headed by Dirk Schmidt-Arras. Our groups collaborate on oncoimmunology questions.
SALK Clinic for Surgery
We work with Univ.-Prof. Dr. Klaus Emmanuel at the Uniklinikum Salzburg-Clinic for Surgery. Direct patient material will allow personalized medicine.
SALK Institute of Pathology
We closely interact with Dr. Karl Sotlar at the Uniklinikum Salzburg-Institute of Pathology on drug targeting and screening efforts.
International Collaborations
Assoc. Prof. Michael Bergmann, MD – Medical University Vienna
Dr. Andreas Bergthaler – Medical University Vienna
Dr. Stefan Constantinescu – de Duve Institute, Ludwig Institute for Cancer Research
Univ. Prof. Dr. Maik Dahlhoff – Veterinary Medicine University Vienna
Dr. Elvin de Araujo – University of Toronto Mississauga
Prof. Dr. Stephan Ehl – University of Freiburg
Dr. Patrick Gunning – University of Glasgow CIVIS
